

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, June 11, 2021

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	X
Mikel Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Matthew Ballard	X
Lenny Petrik, PharmD	X	Bill Snyder, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:04 pm. The minutes of the December meeting were presented. Baack made a motion to approve. Ladwig seconded the motion. The motion was unanimously approved via roll call vote.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from January 1, 2021 to March 31, 2021. A total of 1,718 PAs were reviewed of which 168 requests (9.8%) were received via telephone and 952 requests (55.4%) were received via fax, and 598 (34.8%) were reviewed via electronically. There was a 15% increase of PAs received from the previous quarter. Baack requested an in-depth review of dermatological PAs and Van Gilder requested to review antivirals PAs at the next meeting.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from January 1, 2021 to March 31, 2021. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, amphetamines, and cystic fibrosis correctors. The top 15 therapeutic classes make up 24.86 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.58 % of total claims. HIV integrase inhibitor antiretrovirals made its debut on the top 15 therapeutic classes. Ladwig requested to review compliance of patients on cystic fibrosis drugs. Darger commented on the utilization of all the hemophilia factor products which combined would sum up to a considerable amount. Jockheck noted the utilization of 3 prescriptions for Hemlibre which should lessen the amount of factor products needed, but increased utilization doesn't seem to support it. Utilization of all factor products were requested to review for the next meeting. Darger requested utilization review for Flovent and generics; and saving opportunities for Creon and Zenpep. Baack requested to review diagnosis submitted for Cholbam, for rare bile acid synthesis disorders.

Old Business

90-Day Fill

Jockheck provided an update on the 90-day fill which was implemented on 10/1/2020. A 90-day supply of generic maintenance medication is allowed after member establishes three monthly fills. Utilization increased to an average about 700 prescriptions per month.

Atypical antipsychotic utilization in children

Committee continued the conversation on the proposed PA criteria for prescribers wanting to add a 3 or more atypical antipsychotics. Stanley commented the diagnoses listed are exceedingly broad. In addition, the criteria for depression should be clarified for atypical antipsychotics to be used as augmentation.

Baack was concerned about the age at which the involvement of psychiatrist, developmental pediatrician, child/adolescent psychiatrist or pediatric neurologist involved in care being low. Stanley supported increasing the age edit for requirement for specialist.

Baack requested utilization for members aged 6 to 12 years old on multiple atypical antipsychotics, diagnosis and prescriber information. Committee requested the criteria to be discussed at next meeting. Darger inquired if there was any public comment. There were none.

ADHD utilization

Committee reviewed ADHD utilization in members 21 years and older. They also reviewed the comparison of PMPM and PUPM of other state Medicaid programs. Committee discussed potential PA on Vyvanse for continuation of therapy from minority to maturity age, step therapy requiring dexamethylphenidate first. Committee requesting PA criteria from State B and other Medicaid programs that require step therapy on Vyvanse. Darger inquired if there was any public comment. There were none.

Opioid update

The committee reviewed 1Q2021 opioid outcomes compared to previous quarters from the opioid initiatives. There was a slight increase in opioid utilization and opioid utilizers during first quarter which corresponds to increase in eligible members. The number of members exceeding 180 MED/day continues to decrease quarter over quarter.

Review PA forms and criteria

The committee reviewed all PA criteria currently in effect. Darger made the following recommendations:

- Byvalson – remove PA
- Nucala – add indication for hypereosinophilic syndrome
- Actemera – add indication for systemic sclerosis associated with interstitial lung disease
- Xolair – add indication for Nasal Polyps with a nasal steroid
- Ketoconazole Topical – update title with brand drug names
- Multiple Sclerosis – reevaluate Tysabri for Crohns on the MS PA
- Triptans – consolidate the PA forms if possible
- Nuvigil and Provigil – review need for PA
- Onfi – review need for PA
- Oracea – review need for PA
- Qvalaquin – review need for PA
- Soma 250 – review need for PA
- Ultram ER – review need for PA
- Uloric – review need for PA

Van Gilder made the following recommendation:

- Non-sedating antihistamines – review need for PA

Darger inquired if there was any public comment. There were none. Ladwig made a motion to incorporate changes as discussed and if more input was needed from the committee for deeper discussion, those are to be brought back for the committee's input. Stanley seconded the motion. Motion was passed unanimously.

New Business

Gabapentin high-dose utilization review

The committee reviewed utilization of all gabapentin claims and especially those over 1,800 mg/day. Committee discussed various way to manage the high-dose usage. Baack requested an in-depth review of members taking over 4,800 mg/day. Ladwig requested to quantify early refills to identify creep. Darger inquired if there was any public comment. There were none.

Opioid-Benzodiazepine-stimulant utilization review

The committee reviewed utilization of medications considered high risk combinations. Current utilization of these combinations is lowered than expected. Darger inquired if there was any public comment. There were none.

Imcivree

Imcivree was reviewed. The committee requested to review the proposed PA at the next meeting. Darger inquired if there was any public comment. There were none.

Juxtapid

Juxtapid was reviewed. The committee requested to review the proposed criteria at the next meeting. Darger inquired if there was any public comment. There were none.

Adjournment

The next meeting is scheduled on September 24, 2021. The December meeting is tentatively scheduled on December 10, 2021. The Committee made a motion to adjourn the meeting and everyone seconded the motion. The motion passed unanimously, and the meeting adjourned at 3:00 pm.